Overview of Solid Lipid Nanoparticles in Breast Cancer Therapy.
Kyumin MoAyoung KimSoohyun ChoeMiyoung ShinHyunho YoonPublished in: Pharmaceutics (2023)
Lipid nanoparticles (LNPs), composed of ionized lipids, helper lipids, and cholesterol, provide general therapeutic effects by facilitating intracellular transport and avoiding endosomal compartments. LNP-based drug delivery has great potential for the development of novel gene therapies and effective vaccines. Solid lipid nanoparticles (SLNs) are derived from physiologically acceptable lipid components and remain robust at body temperature, thereby providing high structural stability and biocompatibility. By enhancing drug delivery through blood vessels, SLNs have been used to improve the efficacy of cancer treatments. Breast cancer, the most common malignancy in women, has a declining mortality rate but remains incurable. Recently, as an anticancer drug delivery system, SLNs have been widely used in breast cancer, improving the therapeutic efficacy of drugs. In this review, we discuss the latest advances of SLNs for breast cancer treatment and their potential in clinical use.
Keyphrases
- drug delivery
- fatty acid
- breast cancer risk
- genome wide
- type diabetes
- regulatory t cells
- squamous cell carcinoma
- cardiovascular events
- polycystic ovary syndrome
- childhood cancer
- stem cells
- risk factors
- gene expression
- copy number
- metabolic syndrome
- pregnant women
- dna methylation
- papillary thyroid
- mesenchymal stem cells
- dendritic cells
- transcription factor
- skeletal muscle
- insulin resistance
- reactive oxygen species
- smoking cessation
- low density lipoprotein
- replacement therapy
- genome wide identification